Tecelra (afamitresgene autoleucel)
Adaptimmune Therapeutics · TCR-T Cell Therapy — MAGE-A4 Directed
What is Tecelra? Tecelra (afamitresgene autoleucel, afami-cel) is the first FDA-approved TCR-T cell therapy, indicated for HLA-A*02:01, 02:05, or 02:06 positive adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy.
About Tecelra
| Brand Name | Tecelra |
| Generic / INN | afamitresgene autoleucel |
| Drug Class | TCR-T Cell Therapy — MAGE-A4 Directed |
| Manufacturer | Adaptimmune Therapeutics |
| Administration | IV infusion (autologous, patient-specific) |
| FDA Approval | 2024 |
FDA-Approved Uses for Tecelra
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Unresectable or metastatic synovial sarcoma — HLA-A*02:01, 02:05, or 02:06 positive adult patients with MAGE-A4 positive tumors who received prior chemotherapy
How Does Tecelra Work?
Afami-cel consists of the patient's own T cells engineered to express a T-cell receptor (TCR) targeting MAGE-A4 — a cancer-testis antigen expressed in synovial sarcoma. Unlike CAR-T cells (which target surface proteins), TCR-T cells recognize intracellular antigen peptides presented on HLA molecules on cancer cells, enabling recognition and destruction of tumor cells displaying MAGE-A4/HLA-A*02 complexes.
Dosage & Administration
Single IV infusion following lymphodepleting chemotherapy (fludarabine + cyclophosphamide). Must be administered at certified healthcare facilities. Manufacturing takes approximately 6–8 weeks from T cell collection to infusion.
Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.
Warnings, Precautions & Side Effects
General Warning
Cytokine release syndrome (CRS). Immune effector cell-associated neurotoxicity syndrome (ICANS). Prolonged cytopenias. Serious infections. Secondary T-cell malignancies. Hemophagocytic lymphohistiocytosis (HLH). Available ONLY through the Tecelra REMS Program.
- CRS (boxed warning)
- ICANS (boxed warning)
- Secondary T-cell malignancies
- Prolonged cytopenias
- HLH
- Serious infections
Common Side Effects
- CRS
- Prolonged cytopenias
- Infections
- Fatigue
- Edema
- Nausea
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Cryopreserved product stored at ≤ −130°C. Requires specialized cryogenic shipping and storage.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Tecelra is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Tecelra. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Tecelra
Tecelra (afamitresgene autoleucel) is the first approved TCR-T cell therapy. It uses the patient's T cells engineered with a TCR targeting MAGE-A4, approved for HLA-matched adults with unresectable/metastatic synovial sarcoma.
CAR-T cells use a synthetic receptor to target proteins on the surface of cancer cells. TCR-T cells use a natural T-cell receptor to target intracellular proteins (like MAGE-A4) that are presented on HLA molecules — allowing recognition of targets that cannot be reached by CAR-T approaches.
Two tests are required: HLA typing (must be HLA-A*02:01, 02:05, or 02:06 positive) AND MAGE-A4 expression testing on tumor tissue.
As a 2024 approval, coverage is evolving. Both biomarker tests and full prior authorization with documentation of prior chemotherapy are required. BiologicHealthPlus can assist with access coordination.
Related Medications & Conditions
Related Medications
Yescarta (CAR-T — CD19) · Abecma (CAR-T — BCMA) · Lifileucel (TIL therapy) · Doxorubicin (prior chemo for sarcoma)
Related Conditions
Synovial sarcoma · Soft tissue sarcoma · MAGE-A4 positive tumors